Skip to main content
. 2021 Sep 6;2021(9):CD011556. doi: 10.1002/14651858.CD011556.pub2

An 2006.

Study characteristics
Methods Design: Randomized controlled trial
Setting: Primary care clinics of Veterans Affairs Medical Centers, USA
Recruitment: Invitation letter to primary care patients
Participants 837 people who smoked daily, 26 cpd, av.age 57, 10% F
Interventions Intervention: participants received behavioral counseling via telephone (7 calls over 2 months) with mailing of smoking cessation medications as clinically indicated. Additional calls were placed over a 12‐month period at the discretion of the counselor
Control: participants were mailed self‐help materials and had continued access to clinical smoking cessation services through their Veterans Affairs Medical Center. All of these had referral‐based smoking cessation programs. Program structure varied by site (e.g., number of sessions and group or individual therapy). However, nicotine patches, nicotine gum, and slow‐release bupropion were available at all sites
Outcomes 6m sustained abstinence at 12m
Validation: None
Measures of provider implementation: Assist‐Meds, Arrange
Funding Source Department of Veterans Affairs Health Services Research and Development Service grant SUI 99101‐1
Author's declarations of interest Authors declared that they had no financial conflict of interest.
Notes Strategy: Adjunctive counseling
Level: Patient
Comparison type: Single component vs. standard care
Risk of bias
Bias Authors' judgement Support for judgement
Sequence Generation Low risk Computer‐generated randomization scheme stratified by primary care facility and blocked within sites
Allocation concealment Low risk Computer‐generated
Blinding of outcome assessors
All outcomes High risk Smoking status was self‐reported. Intervention group had greater face‐to‐face contact.
Incomplete outcome data
All outcomes Low risk The overall loss to follow‐up was 14.6% (n = 122/838); 13.9% (n = 58/418) in the intervention group and 15.2% (n = 64/420) in the control group were lost to follow‐up at 12 months